Log in to your Inderes Free account to see all free content on this page.

Skapa användarkonto

Scandion Oncology

Under 1K följer bolaget

Alla

Webcasts

Pressmeddelanden

Tredje part

VisarAlla typer av innehåll

Regulatoriskt pressmeddelande2025-06-25 15:00

Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025

Scandion Oncology

Regulatoriskt pressmeddelande2025-06-25 12:00

Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market

Scandion Oncology

Regulatoriskt pressmeddelande2025-03-27 15:00

Scandion Oncology Announces Results of Annual General Meeting

Scandion Oncology

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

FREE account

Stock market's most popular morning newsletter

Tillgång till analytikerkommentarer och rekommendationer

Vårt eget aktiescreeningsverktyg

PREMIUM account

Alla aktieanalyser och övrigt innehåll

Premiumverktyg (insidertransaktioner och aktiescreeningsverktyg)

Inderes modellportfölj

Skapa användarkonto

Regulatoriskt pressmeddelande2025-03-12 12:10

Scandion Oncology – Notice convening the Annual General Meeting

Scandion Oncology

Regulatoriskt pressmeddelande2025-03-12 12:05

Scandion Oncology - Annual Report 2024

Scandion Oncology

Regulatoriskt pressmeddelande2025-03-12 12:00

Scandion Oncology – Q4 & yearend report 2024

Scandion Oncology

Regulatoriskt pressmeddelande2025-02-26 17:40

Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks

Scandion Oncology

Regulatoriskt pressmeddelande2025-02-26 17:35

Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report

Scandion Oncology

Regulatoriskt pressmeddelande2025-02-26 17:30

Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting

Scandion Oncology

Regulatoriskt pressmeddelande2025-01-13 06:00

Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer

Scandion Oncology

Regulatoriskt pressmeddelande2024-11-20 16:30

Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million

Scandion Oncology

Regulatoriskt pressmeddelande2024-11-14 07:30

Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024

Scandion Oncology

Pressmeddelande2024-11-12 16:54

Redeye: Scandion Oncology Q3 2024 - Searching for a partner

Scandion Oncology

Scandion Oncology, Audiocast with teleconference, Q3'24

Webcast2024-11-11 08:00

Scandion Oncology, Audiocast with teleconference, Q3'24

Scandion Oncology

Regulatoriskt pressmeddelande2024-11-11 06:00

Scandion Oncology – Interim Report Q3 2024

Scandion Oncology

Pressmeddelande2024-11-05 16:00

Invitation to Scandion Oncology webcast and conference call November 11, 2024

Scandion Oncology

Regulatoriskt pressmeddelande2024-11-04 07:30

Scandion Oncology announces the start of the exercise period for warrants of series TO 2

Scandion Oncology

Regulatoriskt pressmeddelande2024-10-31 07:30

Correction: Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology

Regulatoriskt pressmeddelande2024-10-30 16:00

Scandion Oncology announces exercise price for warrants of series TO 2

Scandion Oncology

Pressmeddelande2024-08-29 10:26

Redeye: Scandion Oncology Q2 2024 - Partnership represents best hope

Scandion Oncology

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.